Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Therapy for Rare Spinal Muscular Atrophy Receives FDA Approval



The drug is the first to be approved to treat the rare genetic disease in both adults and children.

Share this!

January 5, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved Biogen’s Spinraza for the treatment of spinal muscular atrophy (SMA). The drug is the first to be approved to treat the rare genetic disease in both adults and children.

“There has been a long-standing need for a treatment for spinal muscular atrophy, the most common genetic cause of death in infants, and a disease that can affect people at any stage of life,” said Dr. Billy Dunn, director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “As shown by our suggestion to the sponsor to analyze the results of the study earlier than planned, the FDA is committed to assisting with the development and approval of safe and effective drugs for rare diseases and we worked hard to review this application quickly; we could not be more pleased to have the first approved treatment for this debilitating disease.”

SMA is characterized by a loss of lower motor neurons, which are responsible for controlling movement, and results in muscle weakness. While the symptoms of the disease vary between individuals, it is often fatal. The incidence of SMA is approximately 1 in every 10,000 live births.

Spinraza was tested in a randomized controlled clinical trial of 121 patients with infantile-onset SMA. An interim analysis found that 40 percent of patients treated with Spinraza saw improvement in motor milestones – such as head control, sitting, rolling, standing and walking – compared to the control group.

Biogen has set the price of the injectable at $125,000 per treatment, which could see patients and payers facing bills up to $750,000 for their first year of treatment with Spinraza. The price would likely decrease to $375,000 for subsequent years, based on the number of treatments necessary, however the drug would likely be taken on a long-term basis.

The cost of Spinraza is surprisingly consistent with other recently-released rare disease drugs. Last year, Gilead Sciences’ hepatitis C drug, Sovaldi, drew criticism over its $84,000 price for a 12-week treatment course. However, the difference between the drugs is that Sovaldi is essentially a cure for some genotypes of hepatitis C; Spinraza has only been shown to improve motor function in some patients with SMA.

Keywords: FDA, Rare Disease, Drug Pricing


Share this with your colleagues!

Insurance Coverage Under the Affordable Care Act Supports Clinical Trial Enrollment, Says Study

July 20, 2017 - Since the Patient Protection and Affordable Care Act (ACA) was passed in 2010, insurance approval for patients wishing to participate in oncology clinical trials has increased, according to a recent study published in the journal, Clinical Cancer Research.

Featured In: Clinical Trial News

FDA Approves Puma Biotechnology’s Extended Adjuvant Therapy for Breast

July 19, 2017 - Puma Biotechnology’s breast cancer drug Nerlynx (neratinib) has been approved by the US Food and Drug Administration (FDA).

Featured In: Biotech News

CAR-T Cell Therapy Shows Promise as Leukemia Treatment in Early Stage Clinical Trial

July 19, 2017 - About 70 percent of clinical trial participants with chronic lymphocytic leukemia experienced tumor shrinkage after being treated with CAR-T immunotherapy, according to researchers at Fred Hutchinson Cancer Research Center.

Featured In: Clinical Trial News


Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know


Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

EDC and eSource: Combined for Better Data and Faster Insights

Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide

How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Copyright © 2016-2017 Honeycomb Worldwide Inc.